A novel lncRNA 495810 promotes the aerobic glycolysis in colorectal cancer by stabilizing pyruvate kinase isozyme M2
Affiliations: Institute of Biotechnology, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, Taiyuan, Shanxi 030006, P.R. China, College of Life Science, Shanxi University, Taiyuan, Shanxi 030006, P.R. China, Institutes of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi 030006, P.R. China
- Published online on: March 17, 2023 https://doi.org/10.3892/ijo.2023.5506
- Article Number: 58
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...
This article is mentioned in:
Aberrant expression of long non‑coding RNA (lncRNA) plays an important role in malignant progression of colon cancer and has become a new therapeutic target. In the present study, it was found that the expression of a novel lncRNA 495810 was significantly upregulated in colon cancer and correlated with poor prognosis in patients with colorectal cancer. The highly expressed lncRNA 495810 promoted the proliferation and inhibited apoptosis of CRC cells. Furthermore, the results of gene enrichment analysis indicated that 495810‑targeted genes were enriched in the glycolysis pathway and overexpression of 495810 enhanced aerobic glycolysis in colon cancer cells. More importantly, the expression of lncRNA 495810 was positively correlated with the glycolytic rate‑limiting enzyme pyruvate kinase isozyme M2 (PKM2). Notably, the data suggested that lncRNA 495810 physically interacted with PKM2 protein and enhanced PKM2 protein stability via the ubiquitin‑proteasome pathway. The present findings suggested that lncRNA 495810, a glycolysis‑related oncogenic lncRNA, is a potential biomarker for predicting prognosis and a therapeutic target for colon cancer.